GPER function in breast cancer: An overview

Frontiers in Endocrinology

Volumn 5, Issue MAY, 2014, Pages

  Lappano, Rosamaria ^a   Pisano, Assunta ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Breast cancer; Estrogen; Estrogen receptor; GPER; GPR30

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; FULVESTRANT; G 15; G PROTEIN COUPLED RECEPTOR 30; G PROTEIN COUPLED RECEPTOR 30 ANTAGONIST; ICI 182, 780; LASOFOXIFENE; MIBE; SOMATOMEDIN C; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; HUMAN; NONHUMAN; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84905499001     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00066     Document Type: Short Survey

References (87)

1. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med (2006) 27:299-402. doi:10.1016/j.mam.2006.07.001
2. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet (2011) 378:771-84. doi:10.1016/S0140-6736(11)60993-8
3. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. National surgical adjuvant breast and bowel project. Cancer Prev Res (Phila) (2010) 3:696-706. doi:10.1158/1940-6207.CAPR-10-0076
4. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. PEARL Study Investigators. N Engl J Med (2010) 362:686-96. doi:10.1056/NEJMoa0808692
5. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. J Steroid Biochem Mol Biol (2003) 87:35-45. doi:10.1016/S0960-0760(03)00384-4
6. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 361:296-300. doi:10.1016/S0140-6736(03)12342-2
7. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol (2007) 14:89-96. doi:10.3747/co.2007.117
8. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol (2013) 3:250. doi:10.3389/fonc.2013.00250
9. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol (2010) 23:S52-9. doi:10.1038/modpathol.2010.55
10. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 13:381-406. doi:10.1007/s10911-008-9099-z
11. Razandi M, Pedram A, Park ST, Levin ER, Oh P, Schnitzer J. Proximal events in signaling by plasma membrane estrogen receptors ERs associate with and regulate the production of caveolin: implications for signalling and cellular actions. J Biol Chem (2003) 278:2701-12. doi:10.1074/jbc.M205692200
12. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J Endocrinol (2010) 204:105-14. doi:10.1677/JOE-09-0242
13. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol (2000) 14:1649-60. doi:10.1210/mend.14.10.0532
14. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem (2004) 279:27008-16. doi:10.1074/jbc.M403588200
15. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J (2009) 28:523-32. doi:10.1038/emboj.2008.304
16. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer (1984) 53:630-43. doi:10.1002/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3
17. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat (2010) 123:87-96. doi:10.1007/s10549-009-0624-6
18. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat (2011) 128:457-66. doi:10.1007/s10549-011-1584-1
19. Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res (2013) 15:R114. doi:10.1186/bcr3581
20. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol (2002) 16:70-84. doi:10.1210/me.16.1.70
21. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol (2010) 320:162-70. doi:10.1016/j.mce.2010.02.006
22. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Breast Cancer Res (2012) 14:R12. doi:10.1186/bcr3096
23. Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat (2012) 133:1025-35. doi:10.1007/s10549-011-1901-8
24. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene (2013) 32:678-88. doi:10.1038/onc.2012.97
25. Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Andò S, et al. The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J Biol Chem (2011) 286:10773-82. doi:10.1074/jbc.M110.172247
26. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res (2010) 70:6036-46. doi:10.1158/0008-5472.CAN-10-0408
27. Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S, et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs). Mol Cell Endocrinol (2013) 376:23-32. doi:10.1016/j.mce.2013.05.023
28. Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua A, Sisci D, et al. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem (2012) 287:43234-45. doi:10.1074/jbc.M112.417303
29. Luo H, Yang G, Yu T, Luo S, Wu C, Sun Y, et al. GPER-mediated proliferation and estradiol production in breast cancer associated fibroblasts. Endocr Relat Cancer (2014) 21(2):355-69. doi:10.1530/ERC-13-0237
30. Lucki NC, Sewer MB. Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J Biol Chem (2011) 286:19399-409. doi:10.1074/jbc.M110.195826
31. Kang K, Lee SB, Jung SH, Cha KH, Park WD, Sohn YC, et al. Tectoridin, a poor ligand of estrogen receptor alpha, exerts its estrogenic effects via an ERK-dependent pathway. Mol Cells (2009) 27:351-7. doi:10.1007/s10059-009-0045-8
32. Dong S, Terasaka S, Kiyama R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut (2011) 159:212-8. doi:10.1016/j.envpol.2010.09.004
33. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect (2012) 120:1177-82. doi:10.1289/ehp.1104526
34. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology (2005) 146:624-32. doi:10.1210/en.2004-1064
35. Thomas P, Dong I. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol (2006) 102:175-9. doi:10.1016/j.jsbmb.2006.09.017
36. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol (2006) 2:207-12. doi:10.1038/nchembio775
37. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr Cancer Drug Targets (2012) 12:531-42. doi:10.2174/156800912800673284
38. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res (2007) 67:1859-66. doi:10.1158/0008-5472.CAN-06-2909
39. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 70:1184-94. doi:10.1158/0008-5472.CAN-09-3068
40. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol (2009) 5:421-7. doi:10.1038/nchembio.168
41. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol (2011) 127:358-66. doi:10.1016/j.jsbmb.2011.07.002
42. Ruan SQ, Wang ZH, Wang SW, Fu ZX, Xu KL, Li DB, et al. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochem Biophys Res Commun (2012) 420:385-90. doi:10.1016/j.bbrc.2012.03.004
43. Li Y, Chen Y, Zhu ZX, Liu XH, Yang L, Wan L, et al. 4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells. Toxicology (2013) 309:61-5. doi:10.1016/j.tox.2013.04.012
44. Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Andò S, et al. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology (2008) 149:5043-51. doi:10.1210/en.2007-1593
45. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol (2009) 23:1815-26. doi:10.1210/me.2009-0120
46. Pupo M, Pisano A, Abonante S, Maggiolini M, Musti AM. GPER activates notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs). Int J Biochem Cell Biol (2014) 46:56-67. doi:10.1016/j.biocel.2013.11.011
47. Jiang QF, Wu TT, Yang JY, Dong CR, Wang N, Liu XH, et al. 17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. J Steroid Biochem Mol Biol (2013) 138:314-24. doi:10.1016/j.jsbmb.2013.07.011
48. Ohshiro K, Schwartz AM, Levine PH, Kumar R. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One (2012) 7:e30725. doi:10.1371/journal.pone.0030725
49. Chen Y, Li Z, He Y, Shang D, Pan J, Wang H, et al. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol (2014) 275(2):176-81. doi:10.1016/j.taap.2014.01.005
50. Marchese S, Silva E. Disruption of 3D MCF-12A breast cell cultures by estrogens-an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis. PLoS One (2012) 7(10):e45767. doi:10.1371/journal.pone.0045767
51. Scaling AL, Prossnitz ER, Hathaway HJ. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer (2014). doi:10.1007/s12672-014-0174-1
52. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res (2013) 15:R64. doi:10.1186/bcr3458
53. Ruan SQ, Wang SW, Wang ZH, Zhang SZ. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression. Mol Med Rep (2012) 6:131-8. doi:10.3892/mmr.2012.874
54. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology (2008) 149:3799-808. doi:10.1210/en.2008-0117
55. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V, Maggiolini M. Cross-talk between GPER and growth factor signaling. J Steroid Biochem Mol Biol (2013) 137:50-6. doi:10.1016/j.jsbmb.2013.03.005
56. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 10:47-60. doi:10.1038/nrd3320
57. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics (1997) 45:607-17. doi:10.1006/geno.1997.4972
58. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 307:1625-30. doi:10.1126/science.1106943
59. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res (2006) 12:6359-66. doi:10.1158/1078-0432.CCR-06-0860
60. Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat (2014) 145:61-71. doi:10.1007/s10549-014-2936-4
61. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17Beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol (2006) 70:1414-23. doi:10.1124/mol.106.026344
62. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol (2006) 20:631-46. doi:10.1210/me.2005-0280
63. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int (2013) 2013:472720. doi:10.1155/2013/472720
64. Chen JQ, Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta (2009) 1796:162-75. doi:10.1016/j.bbcan.2009.06.003
65. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 13:4429-34. doi:10.1158/1078-0432.CCR-06-3045
66. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature (2000) 406:747-52. doi:10.1038/35021093
67. Girgert R, Emons G, Gründker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat (2012) 134:199-205. doi:10.1007/s10549-012-1968-x
68. Steiman J, Peralta EA, Louis S, Kamel O. Biology of the estrogen receptor, GPR30, in triple negative breast cancer. Am J Surg (2013) 206:698-703. doi:10.1016/j.amjsurg.2013.07.014
69. Filardo EJ, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology (2007) 148:3236-45. doi:10.1210/en.2006-1605
70. Sandén C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Mårtensson UE, et al. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol Pharmacol (2011) 79:400-10. doi:10.1124/mol.110.069500
71. Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, et al. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol (2006) 84:287-97. doi:10.1139/y05-127
72. Chotani MA, Flavahan NA. Intracellular α2C-adrenoceptors: storage depot, stunted development or signaling domain? Biochim Biophys Acta (2011) 1813:1495-503. doi:10.1016/j.bbamcr.2011.05.006
73. Yu J, Deliu E, Zhang XQ, Hoffman NE, Carter RL, Grisanti LA, et al. Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem (2013) 288:22481-92. doi:10.1074/jbc.M113.456178
74. Samartzis EP, Noske A, Meisel A, Varga Z, Fink D, Imesch P. The G protein-coupled estrogen receptor (GPER) is expressed in two different subcellular localizations reflecting distinct tumor properties in breast cancer. PLoS One (2014) 9:e83296. doi:10.1371/journal.pone.0083296
75. Chimento A, Casaburi I, Rosano C, Avena P, De Luca A, Campana C, et al. Oleuropein and hydroxytyrosol activate GPER/GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol Nutr Food Res (2013) 58(3):478-89. doi:10.1002/mnfr.201300323
76. Broselid S, Cheng B, Sjöström M, Lövgren K, Klug-De Santiago HL, Belting M, et al. G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients. Clin Cancer Res (2013) 19:1681-92. doi:10.1158/1078-0432.CCR-12-2376
77. Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, et al. GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol (2014) 140(5):713-23. doi:10.1007/s00432-014-1620-8
78. Weißenborn C, Ignatov T, Poehlmann A, Wege AK, Costa SD, Zenclussen AC, et al. GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. J Cancer Res Clin Oncol (2014) 140(4):663-71. doi:10.1007/s00432-014-1598-2
79. Wang C, Lv X, Jiang C, Davis JS. The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. Am J Transl Res (2012) 4:390-402.
80. Wang C, Lv X, He C, Hua G, Tsai MY, Davis JS. The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis (2013) 4:e869. doi:10.1038/cddis.2013.397
81. Isensee J, Meoli L, Zazzu V, Nabzdyk C, Witt H, Soewarto D, et al. Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology (2009) 150:1722-30. doi:10.1210/en.2008-1488
82. Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, et al. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod (2009) 80:34-41. doi:10.1095/biolreprod.108.071175
83. Peyton C, Thomas P. Involvement of epidermal growth factor receptor signaling in estrogen inhibition of oocyte maturation mediated through the G-protein-coupled estrogen receptor (GPER) in zebrafish (Danio rerio). Biol Reprod (2011) 85:42-50. doi:10.1095/biolreprod.110.088765
84. Pang Y, Dong J, Thomas P. Estrogen signaling characteristics of Atlantic croaker G-protein-coupled receptor 30 (GPR30) and evidence it is involved in maintenance of oocyte meiotic arrest. Endocrinology (2008) 149:3410-26. doi:10.1210/en.2007-1663
85. Chimento A, Sirianni R, Delalande C, Silandre D, Bois C, Andò S, et al. 17 Beta-estradiol activates rapid signaling pathways involved in rat pachytene spermatocytes apoptosis through GPR30 and ER alpha. Mol Cell Endocrinol (2010) 320:136-44. doi:10.1016/j.mce.2010.01.035
86. Chimento A, Sirianni R, Zolea F, Bois C, Delalande C, Andò S, et al. GPER and ESRs are expressed in rat round spermatids and mediate oestrogen-dependent rapid pathways modulating expression of cyclin B1 and Bax. Int J Androl (2011) 34:420-9. doi:10.1111/j.1365-2605.2010.01100.x
87. Wang C, Prossnitz ER, Roy SK. G-protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology (2008) 149:4452-61. doi:10.1210/en.2008-0441